diabetestalk.net

Global Human Insulin Market

Global Human Insulin Market 2017-2023

Global Human Insulin Market 2017-2023

Overview: Insulin is a peptide hormone that helps in controlling the absorption of fat and carbohydrate in the body. The human insulin market is anticipated to grow at a robust CAGR during the forecast period due to a high incidence rate of diabetes, globally. The growth in the prevalence rate of diabetes, changes in lifestyles, rising number of obese patients, and increasing geriatric population are the major factors driving the market growth. However, the high cost for the development and production of insulin, manufacturing complexities, and stringent regulatory scenario for the approval of derived products are hampering the growth of the market. The development of pipeline insulin products and expiry of key patents are providing an opportunity for the manufacturers of human insulin. Market Analysis: The Global Human Insulin market is estimated to witness a CAGR of 10.2% during the forecast period 20172023. The human insulin market is analyzed based on three segments top insulin brands, product types, and regions. Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the global human insulin market, followed by Europe, Asia Pacific, and Rest of the World. Nearly half of the market is occupied by North America, with the US being the major contributor to the market growth. Product Analysis: Based on types, the market is segmented into modern human insulin and traditional human insulin. Modern human insulin includes rapid-acting insulin analogs, premixed analogue insulins, and long-acting insulin. Traditional human insulin includes regular human insulin, NPH human insulin, and pre-mixed insulin. Novo Nordisk holds 45.0% share of the total modern insulin Continue reading >>

Global Human Insulin Market 2018-2024 - Key Players Are Novo Nordisk, Sanofi A/s, Eli Lilly & Company, And Astra Zeneca - Researchandmarkets.com

Global Human Insulin Market 2018-2024 - Key Players Are Novo Nordisk, Sanofi A/s, Eli Lilly & Company, And Astra Zeneca - Researchandmarkets.com

DUBLIN--( BUSINESS WIRE )--The "Global Human Insulin Market 2018-2024" report has been added to ResearchAndMarkets.com's offering. The Global Human Insulin market is estimated to witness a CAGR of 10.2% during the forecast period 2017-2023 The growth in the prevalence rate of diabetes, changes in lifestyles, rising number of obese patients, and increasing geriatric population are the major factors driving the market growth. However, the high cost for the development and production of insulin, manufacturing complexities, and stringent regulatory scenario for the approval of derived products are hampering the growth of the market. The development of pipeline insulin products and expiry of key patents are providing an opportunity for the manufacturers of human insulin. Based on types, the market is segmented into modern human insulin and traditional human insulin. Modern human insulin includes rapid-acting insulin analogs, premixed analogue insulins, and long-acting insulin. Traditional human insulin includes regular human insulin, NPH human insulin, and pre-mixed insulin. Novo Nordisk holds 45.0% share of the total modern insulin market. Lantus is the major insulin drug in the market. Due to the loss of patents, the drug has got competition in the form of biosimilar by name Basaglar from Eli Lilly. After the loss of share for its biosimilar counterpart, the drug lost its value for its follow-up drug Toujeo. Since the launch of Toujeo in April 2015, the company has been switching over as many patients as possible to the newer drug to fill the sales gap caused by the reduced revenue of Lantus. Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca PLC are the key players in the market. The other prominent players in the market include Biocon, Julphar, Wockhardt, G Continue reading >>

Global Human Insulin Market (size Of $24 Billion In 2014) To Witness 13% Cagr During 2015 - 2020

Global Human Insulin Market (size Of $24 Billion In 2014) To Witness 13% Cagr During 2015 - 2020

Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 Jul 28, 2015, 08:30 ET from P&S Market Research P&S Market Research Logo (PRNewsFoto/P&S Market Research) P&S Market Research Logo (PRNewsFoto/P&S Market Research) P&S Market Research releases a new research report with market overview, trends, DRO analysis, market segmentation, market size, share, forecast, porter analysis, recent developments, competitive scenario and top competitor profiles in: Global Industry Insight: Human Insulin Market Development and Demand Forecast to 2020 (Logo: ) Explore more about Global Human Insulin Market: The global human insulin market was valued at $23,981.6 million in 2014. The market is expected to grow at a CAGR of 12.5% during the period 2015 to 2020, to reach $48,487.7 million value by 2020. The global human insulin market is being driven by increasing prevalence of diabetic population, and rise in aging population. Diabetes is a chronic and non-communicable disease, and its global prevalence is increasing enormously. Rising prevalence of obesity, rising awareness about diabetic care, and technological advancement in insulin delivery devices are some of the factors driving the growth of the globalhuman insulin market. Growing demand of biosimilar drugs, due to its cost effectiveness, pose an opportunity for the growth of the human insulin market. In addition, increasing usage of insulin pens for the administration of insulin helps to inject the accurate dose of insulin at a time. However, high insulin analog cost and strict regulatory requirements for approval of human insulin are inhibiting the growth of the global human insulin market. On the basis of type of human insulin, the modern human insulin commands the larger share in the g Continue reading >>

Global Human Insulin Market - World Human Insulin Market Size, Trends, Analysis And Segment Forecasts To 2020 - Human Insulin Industry Research, Outlook, Application, Product, Share, Growth, Key Opportunities, Dynamics, Analysis, Human Insulin Report - Grand View Research Inc

Global Human Insulin Market - World Human Insulin Market Size, Trends, Analysis And Segment Forecasts To 2020 - Human Insulin Industry Research, Outlook, Application, Product, Share, Growth, Key Opportunities, Dynamics, Analysis, Human Insulin Report - Grand View Research Inc

Global Human Insulin Market - World Human Insulin Market Size, Trends, Analysis And Segment Forecasts To 2020 - Human Insulin Industry Research, Outlook, Application, Product, Share, Growth, Key Opportunities, Dynamics, Analysis, Human Insulin Report - Grand View Research Inc Human Insulin Market Analysis, Market Size, Application Analysis, Regional Outlook, Competitive Strategies And Forecasts, 2014 To 2020 The rising prevalence of diabetes worldwide coupled with the growing obese population due to the change in lifestyle are the major factors driving the human insulin market. Furthermore, the introduction of pen devices as well as the safety pen needles for effective delivery of insulin are the propelling factors for the global human insulin market. This is owing to various advantages while injecting insulin through safety pens as compared to the other standard needles. The human insulin market consists various opportunities such as implementation of regulations against needlestick injuries, needle anxiety, and growing awareness associated to the danger of blood borne pathogen transmission. Furthermore, growing demand for biosimilar drugs due to their cost effectiveness are also the high impact rendering drivers for the human insulin market. The human insulin market is analyzed by segmenting the market on the basis of product type and brands. On the basis of product type, the market is segmented as short acting human insulin, intermediate acting human insulin, long acting human insulin, fast acting human insulin and premixed human insulin. The short acting human insulin, also known as regular insulin, covers the largest share in the market owing to its slow acting and adjustability with the human body. On the basis of brands, the market is segmented into Humalog, Api Continue reading >>

Global Human Insulin Market (size Of $24 Billion In 2014) To Witness 13% Cagr During 2015 - 2020

Global Human Insulin Market (size Of $24 Billion In 2014) To Witness 13% Cagr During 2015 - 2020

Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR during 2015 - 2020 P&S Market Research releases a new research report with market overview, trends, DRO analysis, market segmentation, market size, share, forecast, porter analysis, recent developments, competitive scenario and top competitor profiles in: Global Industry Insight: Human Insulin Market Development and Demand Forecast to 2020 Explore detailed TOC and Scope of the report: The global human insulin market was valued at $23,981.6 million in 2014. The market is expected to grow at a CAGR of 12.5% during the period 2015 to 2020, to reach $48,487.7 million value by 2020. The global human insulin market is being driven by increasing prevalence of diabetic population, and rise in aging population. Diabetes is a chronic and non-communicable disease, and its global prevalence is increasing enormously. Rising prevalence of obesity, rising awareness about diabetic care, and technological advancement in insulin delivery devices are some of the factors driving the growth of the global human insulin market . Growing demand of biosimilar drugs, due to its cost effectiveness, pose an opportunity for the growth of the human insulin market. In addition, increasing usage of insulin pens for the administration of insulin helps to inject the accurate dose of insulin at a time. However, high insulin analog cost and strict regulatory requirements for approval of human insulin are inhibiting the growth of the global human insulin market. On the basis of type of human insulin, the modern human insulin commands the larger share in the global market. The modern human insulin is also expected to grow at a CAGR (of 13%) than traditional human insulin during 2015 to 2020. The modern human insulin can be furthe Continue reading >>

Global Human Insulin Market To Reach 8.3% Cagr By 2015: Analysis, Opportunities, Challenges, & Forecast

Global Human Insulin Market To Reach 8.3% Cagr By 2015: Analysis, Opportunities, Challenges, & Forecast

Global Human Insulin Market to Reach 8.3% CAGR by 2015: Analysis, Opportunities, Challenges, & Forecast Zion Market Research has published a new report titled Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application -Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 2021According to the report, the global Human Insulin Market accounted for USD 27.00 billion in 2015 and is expected to reach USD 43.6 billion by 2021, growing at a CAGR of around 8.3% between 2016 and 2021. Diabetes is described as a group of metabolic diseases in which the person has high blood glucose level than normal, either because insulin production is inadequate, or because the body's cells do not respond properly to insulin. Diabetes is a lifelong condition that is characterized by a raised blood glucose level. Diabetes is characterized into two types of diabetes: Insulin dependent diabetes mellitus (type 1) and Non-insulin dependent diabetes mellitus (type 2). Signs of diabetes include an increased sense of thirst, frequent urination, fatigue, weight and muscle loss, delayed wound healing and blurred vision. Human insulin therapy is utilized for the treatment of both type1 and type 2 diabetes mellitus. Request Free Sample Research Report @ Global rise in human insulin market is mainly due to the increase in diabetic disorder patient across the globe. Moreover, the factors those are responsible for increasing numbers of diabetic population globally include sedentary lifestyles, obesity, rise in geriatric populations and poor healthcare services. Furthermore, advanced technology like pen device, safety pen needles for efficient delivery of insulin is fueling the growth of global human insulin market. However, production co Continue reading >>

Human Insulin Market Worth 39.13 Billion Usd By 2020

Human Insulin Market Worth 39.13 Billion Usd By 2020

HOME Press Releases Human Insulin Market worth 39.13 Billion USD by 2020 Human Insulin Market worth 39.13 Billion USD by 2020 The report Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020 analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Browse75 market tables and53 figures spread through157 pagesand in-depth TOC on "Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020" Early buyers will receive 10% customization on reports. The Global Human Insulin Market Is Poised to reach ~USD 39.13 Billion by 2020, growing at a CAGR of 8.1% from 2015 to 2020 and studies the global human insulin market over the forecast period of 2015 to 2020. On the basis of products, the global human insulin market is classified into two segments, namely, drugs and delivery devices. Human insulin drugs market has been further divided on the basis of drug type (rapid-acting, intermediate-acting, long-acting, short-acting, and premixed) and drug brands (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid, Insulatard, Mixtard, and Other Biosimilar Brands). Furthermore, human insulin delivery devices market is segmented into insulin pens (reusable & disposable), pen needles (standard & safety), and conventional syringes. Additionally, global human insulin market is classified on the basis Continue reading >>

Global Insulin Market 2017: Focus On Insulin Delivery Devices - Market Outlook 2022 Approval Of Glargine Basaglar - The First Biosimilar Insulin In The Us - Research And Markets

Global Insulin Market 2017: Focus On Insulin Delivery Devices - Market Outlook 2022 Approval Of Glargine Basaglar - The First Biosimilar Insulin In The Us - Research And Markets

Global Insulin Market 2017: Focus On Insulin Delivery Devices - Market Outlook 2022 Approval Of Glargine Basaglar - The First Biosimilar Insulin In The US - Research And Markets Dublin /PRNewswire/ -- Research and Markets has announced the addition of the "Global Insulin Market: Focus on Insulin Delivery Devices - Market Outlook 2022" report to their offering. Growth of the global insulin market is propelled by increasing prevalence diabetes, rise in geriatric population, growing obese population, propagation of diabetes management awareness and government impetus. Major factors restraining growth of the market are high cost of insulin, insurance coverage issue, high competition and stringent regulatory pressure. The report is segmented on the basis of insulin delivery devices market such as syringes, vials, insulin pumps, etc. Market analysis for these devices is provided for current as well as forecasted period. Furthermore, insulin therapy market assessment is done across major markets such as Europe, North America and China. In-depth analysis of insulin therapy in aforementioned regions is done on the basis of overall insulin market size and market share by treatment option. Leading industry players operating in the global insulin therapy market include Novo Nordisk, Sanofi Aventis, Eli Lilly and Company; and Merck & Co. These industry players are profiled herein based on attributes such as business overview, product segments, financial and business strategies. The report also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. D Continue reading >>

Human Insulin Market

Human Insulin Market

Global Market Study on Human Insulin: Asia Pacific to Witness fastest Growth by 2020 Diabetes refers to a group of metabolic disease characterized by high blood sugar level. It occurs due to inadequate secretion of insulin inside the pancreas. Some of the common symptoms for diabetes are frequent urination, excessive thirst, increased hunger, weight loss and tiredness. Type 1, type 2 and gestational diabetes are three common types of diabetes. Type 1 diabetes is an autoimmune disease occurred due to high blood glucose level whereas, type 2 diabetes is a lifelong chronic disease caused due to excess secretion of insulin inside the body. Type 2 diabetes is the common form of diabetes. Diabetes is more common in aged people; however, its prevalence is steadily increasing in adults and children. Severe problems such as blindness, kidney failure, coronary heart disease and strokes may result due to lack of proper treatment of diabetes. It also causes blindness, amputation, and kidney failure. Diabetes can be treated by maintaining appropriate levels of insulin in the body. Insulin helps control blood glucose levels and subsequently drives energy for the proper execution of all cellular and biological activities. North America dominates the global market for human insulin due to large number of aging the population, increasing prevalence of diabetes and diabetes-related disorders. In addition, availability of technological advanced human insulin infusion devices is also boosting the growth of the market. Asia Pacific is expected to show fast growth rates in the next five years in the global human insulin market. China and India are expected to be the fastest-growing human insulin markets in the Asia Pacific region. In addition, the human insulin market in Japan is also growi Continue reading >>

At 8.3% Cagr, Global Human Insulin Market To Hit Us $43.6 Bn By 2021: Zion Market Research

At 8.3% Cagr, Global Human Insulin Market To Hit Us $43.6 Bn By 2021: Zion Market Research

At 8.3% CAGR, Global Human Insulin Market to Hit US $43.6 Bn by 2021: Zion Market Research According to the report, the global Human Insulin Market accounted for USD 27.00 billion in 2015 and is expected to reach USD 43.6 billion by 2021, growing at a CAGR of around 8.3% between 2016 and 2021. Sarasota, FL, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application -Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 2021. According to the report, the global Human Insulin Market accounted for USD 27.00 billion in 2015 and is expected to reach USD 43.6 billion by 2021, growing at a CAGR of around 8.3% between 2016 and 2021. The global human insulin market is expected to witness significant growth during the forecast period. This growth is attributed due to increasing the risk of diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. An insulin regimen is often required in the treatment of gestational diabetes and diabetes-associated with certain conditions or syndromes (e.g.pancreatic diseases, drug- or chemical-induced diabetes, endocrinopathies, insulin-receptor disorders, certain genetic syndromes). In all instances of insulin use, the insulin dosage must be individualized and balanced with medical nutrition therapy and exercise. Browse through 13 Market Tables and 25 Figures spread through 110 Pages and in-depth TOC on "Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application and Forecast 2015 2021. Request Free Sample copy of Global Hu Continue reading >>

Global Human Insulin Market 2018-2024 - Key Players Are Novo Nordisk, Sanofi A/s, Eli Lilly & Company, And Astra Zeneca - Researchandmarkets.com

Global Human Insulin Market 2018-2024 - Key Players Are Novo Nordisk, Sanofi A/s, Eli Lilly & Company, And Astra Zeneca - Researchandmarkets.com

Global Human Insulin Market 2018-2024 - Key Players are Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca - ResearchAndMarkets.com The "Global Human Insulin Market 2018-2024" report has been added to ResearchAndMarkets.com's offering. The Global Human Insulin market is estimated to witness a CAGR of 10.2% during the forecast period 2017-2023 The growth in the prevalence rate of diabetes, changes in lifestyles, rising number of obese patients, and increasing geriatric population are the major factors driving the market growth. However, the high cost for the development and production of insulin, manufacturing complexities, and stringent regulatory scenario for the approval of derived products are hampering the growth of the market. The development of pipeline insulin products and expiry of key patents are providing an opportunity for the manufacturers of human insulin. Based on types, the market is segmented into modern human insulin and traditional human insulin. Modern human insulin includes rapid-acting insulin analogs, premixed analogue insulins, and long-acting insulin. Traditional human insulin includes regular human insulin, NPH human insulin, and pre-mixed insulin. Novo Nordisk holds 45.0% share of the total modern insulin market. Lantus is the major insulin drug in the market. Due to the loss of patents, the drug has got competition in the form of biosimilar by name Basaglar from Eli Lilly. After the loss of share for its biosimilar counterpart, the drug lost its value for its follow-up drug Toujeo. Since the launch of Toujeo in April 2015, the company has been switching over as many patients as possible to the newer drug to fill the sales gap caused by the reduced revenue of Lantus. Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca Continue reading >>

Human Insulin Market By Types (traditional Human Insulin, Premixed Traditional, Intermediate Acting, Modern Human Insulin, Premixed Modern, Long Acting, Rapid Acting) - Global Opportunity Analysis And Industry Forecast, 2017-2023

Human Insulin Market By Types (traditional Human Insulin, Premixed Traditional, Intermediate Acting, Modern Human Insulin, Premixed Modern, Long Acting, Rapid Acting) - Global Opportunity Analysis And Industry Forecast, 2017-2023

Insulin regulates fat and carbohydrate metabolism in the body. It is a peptide hormone, which is secreted in the pancreas by beta cells of the islets of Langerhans and it helps to regulate the glucose metabolism. It causes skeletal muscle cells and fat tissues to absorb glucose from the blood. The global human insulin market is expected to grow at healthy CAGR during the forecast period due to high prevalence of diabetes, worldwide. In-depth analysis of the global human insulin market focuses on various aspects of the market such as market trends, market drivers, restraints and opportunities. Competitive landscape section focuses on key leaders within the global human insulin market and their major growth strategies. Detailed analysis of segments helps in understanding market dynamics and would be beneficial for market professionals. The growth of global human insulin market is primarily attributed to rising prevalence of diabetes. The factors that contribute to growing number of diabetic patient globally include changes in lifestyles, growing number of obese as well as geriatric population and inadequate healthcare services. Favorable government policies and technological advances such as innovation of insulin pens have also fueled the growth of this market. However, cost of production, manufacturing complexities and critical regulatory requirements for the approval of biotechnology derived products are the factors that could hinder the growth of global human insulin market. Pipeline insulin products and untapped emerging economies are the promising opportunities for the manufacturers of global human insulin. The global human insulin market is segmented by product type into Traditional and Modern Human Insulin. Traditional Human Insulin is segmented as Premixed, Inter Continue reading >>

Global Human Insulin Market Is Set For A Rapid Growth And Is Expected To Reach Usd 43.6 Billion By 2021

Global Human Insulin Market Is Set For A Rapid Growth And Is Expected To Reach Usd 43.6 Billion By 2021

Global Human Insulin Market Is Set for a Rapid Growth and is Expected to Reach USD 43.6 Billion by 2021 Zion Market Research has published a new report titled Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application -Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 2021 According to the report, the global Human Insulin Market accounted for USD 27.00 billion in 2015 and is expected to reach USD 43.6 billion by 2021, growing at a CAGR of around 8.3% between 2016 and 2021. The global human insulin market is expected to witness significant growth during the forecast period. This growth is attributed due to increasing the risk of diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. An insulin regimen is often required in the treatment of gestational diabetes and diabetes-associated with certain conditions or syndromes (e.g.pancreatic diseases, drug- or chemical-induced diabetes, endocrinopathies, insulin-receptor disorders, certain genetic syndromes). In all instances of insulin use, the insulin dosage must be individualized and balanced with medical nutrition therapy and exercise. Browse the full "Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 2021" report at Drugs segment dominated the human insulin market across the globe in 2015 followed by drug delivery device due to its excess demand, rising proportion of aging population in developed countries, growing research & development for drug discovery & dev Continue reading >>

Human Insulin Market Estimated To Register A Cagr Of 12.1 % By 2027: Asserts Mrfr

Human Insulin Market Estimated To Register A Cagr Of 12.1 % By 2027: Asserts Mrfr

Human Insulin Market Estimated to Register a CAGR of 12.1 % By 2027: Asserts MRFR PUNE, India, July 26, 2017 /PRNewswire/ -- Market Research Future published a cooked research report on "Global Human Insulin Market Research Report - Forecast to 2027" Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027. Biocon Ltd. (India), Tonghua Dongbao Pharmaceuticals Co., Ltd. (China), Adocia (France.), Merck & Co. (U.S.), Julphar (UAE), Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc (U.K.), Oramed Pharmaceuticals, Inc. (Israel), Novo Nordisk A/S (Denmark), Pfizer, and Sanofi are some of the prominent players competing in the Global Human Insulin Market and are profiled in MRFR Analysis. The Human Insulin Market is growing with the rapid pace; mainly due to the increasing prevalence of diabetic population. According to a recent study report published by the Market Research Future, the global Human Insulin market is forecasted to gain prominence over the forthcoming years. The market is expected to grow at a rapid pace during the forecast period. The Human Insulin Market is projected to demonstrate a spectacular growth by 2027, surpassing its previous growth records in terms of value with a striking two-digit CAGR of 12.1% during the anticipated period (2016 2027). The major factors contributing to the market growth are; increase in prevalence of diabetic population, rise in geriatric population, rising awareness of diabetes and rising prevalence of obesity. However, strict regulatory requirements for approval of insulin and high cost of analog are inhibiting the growth of the global human insulin market. Along with that, delayed onset of action, and various side effects of human insulin are also limiting the growth of this market across the globe. Althoug Continue reading >>

Human Insulin Market - Drugs, Type, Brands, Delivery Devices, Applications - Forecasts To 2020 - Ref #mm000025

Human Insulin Market - Drugs, Type, Brands, Delivery Devices, Applications - Forecasts To 2020 - Ref #mm000025

Human Insulin Market - Drugs, Type, Brands, Delivery Devices, Applications - Forecasts to 2020 - ref #MM000025 Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020 The global human insulin market is poised to reach ~USD 39.13 billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. North America is expected to hold the largest share of the global human insulin market in 2015. Market growth of human insulin products is being propelled by growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of human insulin market. In addition, high product manufacturing costs is posing significant challenges for market growth during the forecast period. In this report, the global human insulin market is segmented on the basis of basis of products (human insulin biologics, insulin analogs & biosimilars, and delivery devices), drug type (rapid-acting, intermediate-acting, long-acting, short-acting, and premixed), drug brand (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid, Insulatard, Mixtard, and Other Biosimilar Brands), delivery devices [insulin pens (reusable & disposable), pen needles (standard & safety), and conventional syringes], and applications (type I diabetes & type II diabetes). Human insulin drugs segment is expected to account for the larger share of the glo Continue reading >>

More in insulin